Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Quoin Pharmaceuticals Ltd.

NASDAQ: QNRX · Life Sciences · 7 alerts · CIK 1671502

Share price
$3.56Close, Nov 16
Market cap
$250M
Shares outstanding
70.29MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Quoin Pharmaceuticals Ltd. filings on SEC EDGAR ↗

5:26 PM ET 8-K
Capital Raise

Quoin Pharmaceuticals Capital Raise

Quoin Pharmaceuticals entered into an at-the-market (ATM) sales agreement with Leerink Partners LLC to sell American Depositary Shares (ADSs) from time to time. Leerink Partners will act as the sales agent and receive a 3.0% commission on gross proceeds from any sales made under the program.

Counterparty
Leerink Partners LLC
6:35 AM ET 8-K
Clinical Trial Data

Quoin Pharmaceuticals Clinical Trial Data

Quoin Pharmaceuticals announced the publication of a peer-reviewed case report detailing 21 months of compassionate use treatment with QRX003 in a pediatric Netherton Syndrome patient, showing an improvement from severe to clear skin. The company also reaffirmed that its ongoing Phase 2/3 study of QRX003 expects to complete recruitment by the end of 2026 with topline data anticipated in Q2 2027.

Term
21 months
4:17 PM ET 8-K
Regulatory Approval

Quoin Pharmaceuticals Regulatory Approval

Quoin Pharmaceuticals announced that the FDA has granted Fast Track Designation to its lead asset, QRX003, for the treatment of Peeling Skin Syndrome. This is the first-ever Fast Track Designation granted for this rare genetic skin disease, which currently has no approved treatments. The company expects to initiate a Phase 2/3 clinical study for the indication in the second half of 2026.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.